Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Medice Arzneimittel Pütter GmbH & Co KG |
---|---|
Information provided by: | Medice Arzneimittel Pütter GmbH & Co KG |
ClinicalTrials.gov Identifier: | NCT00619840 |
Investigation of efficacy and tolerability of extended-release MPD in adults with ADHD, compared with a placebo, and to acquire knowledge through long-term observation of adults
Condition | Intervention | Phase |
---|---|---|
Attention Deficit Hyperactivity Disorder |
Drug: methylphenidate hydrochloride Drug: Placebo |
Phase III |
Study Type: | Interventional |
Study Design: | Treatment, Randomized, Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Placebo Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | Placebo-Controlled Multi-Centre Double-Blind Trial for Adults With Extended-Release Methylphenidate for ADHD |
Enrollment: | 363 |
Study Start Date: | November 2004 |
Primary Completion Date: | May 2006 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Active Comparator |
Drug: methylphenidate hydrochloride
sustained release, 10 mg capsule 1-3 capsules twice daily according to an individual titration schedule
|
2: Placebo Comparator |
Drug: Placebo
10 mg capsule 1-3 capsules twice daily according to an individual titration schedule
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Germany, Sarland | |
Institute of Forensic Psychology and Psychiatry | |
Homburg/Saar, Sarland, Germany, 66421 |
Principal Investigator: | Michael Rösler, Prof. Dr. | Institute of Forensic Psychology and Psychiatry, University of Saarland |
Responsible Party: | Medice Arzneimittel Pütter GmbH & Co. KG ( Dr. Roland Fischer/Head of Medical Dept. ) |
Study ID Numbers: | 6520-9979-06 |
Study First Received: | February 11, 2008 |
Last Updated: | February 11, 2008 |
ClinicalTrials.gov Identifier: | NCT00619840 History of Changes |
Health Authority: | Germany: Federal Institute for Drugs and Medical Devices |
ADHD Attention Deficit Hyperactivity Disorder adult methylphenidate hydrochloride Medikinet retard long-term observation |
controlled clinical trial safety randomized, double-blind, placebo-controlled trial treatment central nervous system stimulants therapeutic uses |
Dopamine Uptake Inhibitors Neurotransmitter Agents Attention Deficit and Disruptive Behavior Disorders Methylphenidate Central Nervous System Stimulants Dyskinesias Signs and Symptoms |
Dopamine Attention Deficit Disorder with Hyperactivity Mental Disorders Mental Disorders Diagnosed in Childhood Hyperkinesis Neurologic Manifestations Dopamine Agents |
Dopamine Uptake Inhibitors Neurotransmitter Uptake Inhibitors Neurotransmitter Agents Molecular Mechanisms of Pharmacological Action Nervous System Diseases Physiological Effects of Drugs Attention Deficit and Disruptive Behavior Disorders Methylphenidate Central Nervous System Stimulants Dyskinesias |
Pharmacologic Actions Signs and Symptoms Attention Deficit Disorder with Hyperactivity Mental Disorders Therapeutic Uses Mental Disorders Diagnosed in Childhood Hyperkinesis Neurologic Manifestations Dopamine Agents Central Nervous System Agents |